Ashley Touchton
Family · Georgetown, DENPI 1679962146
Payments from drug & device makers
Across 123 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$447
- Lilly USA, LLC$229
- AstraZeneca$207
- AbbVie$195
- Pfizer$128
- Indivior Inc.$87
- plus $831 from 23 others
What the payments were for
- Food & beverage$2,124100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $447 |
| Lilly USA, LLC | 13 | $229 |
| AstraZeneca | 12 | $207 |
| AbbVie | 10 | $195 |
| Pfizer | 7 | $128 |
| Indivior Inc. | 4 | $87 |
| Boehringer Ingelheim | 5 | $81 |
| Amgen | 5 | $79 |
| Dexcom, Inc. | 4 | $75 |
| Novartis | 4 | $55 |
| Astellas Pharma US Inc | 4 | $54 |
| Eisai Inc. | 3 | $50 |
| Bayer | 3 | $45 |
| Alkermes, Inc. | 2 | $42 |
| Braeburn Inc. | 2 | $38 |
| Johnson & Johnson | 1 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $34 |
| Avanir Pharmaceuticals, Inc. | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| VBI Vaccine (delaware) Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Medtronic | 1 | $13 |
| Merck | 1 | $12 |
How this compares
$2,124 in reported general payments places this provider in the 75th percentile of 523 family providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $42,976 |
| EliquisApixaban | 38 | $35,881 |
| JanuviaSitagliptin Phosphate | 45 | $33,524 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $28,825 |
| FarxigaDapagliflozin Propanediol | 25 | $28,282 |
| MyrbetriqMirabegron | 42 | $24,978 |
| TrulicityDulaglutide | 22 | $21,424 |
| JardianceEmpagliflozin | 28 | $20,760 |
| LinzessLinaclotide | 34 | $18,893 |
| RybelsusSemaglutide | 13 | $14,704 |
| Repatha SureclickEvolocumab | 19 | $14,055 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $8,703 |
| Esomeprazole Magnesium | 57 | $7,870 |
| Spiriva RespimatTiotropium Bromide | 11 | $7,577 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $6,892 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $447 | $57,68049 claims |
| PfizerEliquis | $128 | $35,88138 claims |
| MerckJanuvia | $12 | $33,52445 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $81 | $28,33739 claims |
| AstraZenecaFarxiga | $207 | $28,28225 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $24,97842 claims |
| Lilly USA, LLCTrulicity | $229 | $21,42422 claims |
| AbbVieLinzess | $195 | $18,89334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 523 family providers in Delaware.
Other family in Georgetown
- Abby AllenGeorgetown$43K
- Jennifer CallardGeorgetown$13K
- Candice RobertsGeorgetown$8K
- Brandi GreggeMiddletown$110K
- Tracy EstesWilmington$59K
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Taylor HodgesLewes$33K
- Jodi KahanWilmington$21K
- Valerie HarrisonBridgeville$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.